NG
CLDX icon

NatWest Group’s Celldex Therapeutics CLDX Stock Holding History

NatWest Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,246
Closed -$355K – 168
2015
Q3 		$355K Buy
+2,246
New +$636K 0.01% 318
2015
Q2 		– Sell
-2,246
Closed -$939K – 388
2015
Q1 		$939K Buy
+2,246
New +$803K 0.01% 228

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

NatWest Group's CLDX Position: Q4 2015 in Review

NatWest Group sold out of Celldex Therapeutics (CLDX) in Q4 2015, closing a stake of 2,246 shares — an estimated $355K sold.

NatWest Group first reported a position in CLDX in Q1 2015 and held it in 2 quarters. The position peaked at $939K in Q1 2015. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • NatWest Group reported no remaining Celldex Therapeutics position as of Q4 2015 after selling out during the quarter.
  • NatWest Group sold 2,246 Celldex Therapeutics shares in Q4 2015, an estimated $355K.
  • NatWest Group first reported a position in Celldex Therapeutics in Q1 2015 and held it in 2 quarters.
  • NatWest Group's Celldex Therapeutics position peaked at $939K in Q1 2015.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on NatWest Group's 13F filing for Q4 2015, filed 16 Feb 2016.